Next Generation Blood Testing
Anti-microbiote antibodies are contributing to inflammatory bowel diseases diagnostic. Miniaturization and combination of the assays lead to generate a larger set of data and thus to get the immune profile of anti-microbiome.
Key Points of InTest
- Easy to process: the assay is based on an ELISA-like protocol,
- Improved sensitivity and specificity: thanks to assay combination, final results are improved
- Up to date: current test can be upgraded with new biomarkers as soon as the benefits have been demonstrated.
Downloads
High Definition Diagnostic Solutions for Precision Medicine
Driven by its unique expertise in biology and biochemistry, Innobiochips develops breakthrough solutions that significantly improve the accuracy and productivity of in vitro diagnostic approaches.
15 employees
10 years of ISO 13485 certification
3 CE marked solutions developed
1M biological tests produced a year and sold all over the world
Building the most advanced diagnosis technology
Transplantation
Transplantation is a critical treatment that faces many challenges to ensure perfect donor/recipient compatibility. Innobiochips has adapted its Siryus technology to offer a novel solution to assess the recipient's reaction to their transplant in order to drastically reduce rejection.
Transfusion
Blood grouping approaches have not evolved in years. The process remains highly repetitive and resource intensive. Innobiochips will introduce a next-generation blood testing and grouping solution in 2024: Omnys. Based on breakthrough technologies, Omnys enables high-resolution testing of blood components: Standard ABO/D typing, phenotyping, advanced phenotyping and IAT.
Infectious diseases
Innobiochips is at the forefront of developing high-resolution multiplex assays that are revolutionizing infectious disease diagnostics. In particular, our team has developed the most advanced COVID-19 diagnostic tool based on its proprietary technology: Covidiag.
Microbiota
Advances in molecular biology have revealed the intricate relationship between the microbiota and various diseases, providing unprecedented opportunities for novel diagnostic solutions. Innobiochips' high-resolution multiplexed diagnostic technologies can detect and characterize anti-microbiota antibodies, providing accurate and valuable insights into an individual's health status.
News
Mission statement
At the forefront of life sciences research, Innobiochips uses the latest scientific developments to improve the precision, specificity and performance of human health diagnostics.
Our goals: to improve laboratory productivity and to open new perspectives for healthcare professionals to better detect and monitor pathological phenomena.
Unique strengths
Innobiochips' teams combine excellent strategic vision, strong engineering skills, complete mastery of regulatory issues and significant manufacturing capabilities.
In close contact with diagnostic labs and clinicians , Innobiochips mobilizes these skills to translate scientific advances into turnkey solutions for healthcare professionals and patients.
Since its creation in 2008, Innobiochips has maintained its pioneering spirit and a highly horizontal, agile organization to accelerate developments and maintain a wide technological lead on the market.
Achievements
Innobiochips is developing a diversified portfolio of innovative diagnostic solutions in several key healthcare markets: transplantation, inflammation, infectious diseases and blood transfusion.
| Regulatory approval
Corporate governance
Since its creation in 2008, Innobiochips' governance has evolved significantly to keep pace with the company's rapid growth.
Founded and developed by two healthtech entrepreneurs with a passion for diagnostic technologies, Innobiochips has built a management structure around its core competencies: R&D, design, industrialization and regulatory affairs.
A strategic committee, composed of managers and investors with experience in the life sciences sector, supports the company's development. A Scientific Committee, composed of experts in human health diagnostics technologies and markets, guides and validates the R&D efforts of Innobiochips' teams.
Key figures
15employees
10years of ISO 13485 certification
3CE marked solutions developed
1Mbiological tests produced a year and sold all over the world
3international patents
Next Generation Blood Testing
Ultimate compatibility.
Maximal sustainability.
Discover the next generation standard for multiplex blood testing and grouping.
Omnys is based on breakthrough technologies that enable high-resolution testing of blood components: Standard ABO/D typing, Phenotyping, Extended phenotyping and IAT. Omnys enables clinicians to perform multiplex testing with unmatched precision, reliability, efficiency... And minimal sample volumes!
Multiply lab productivity by 4
Omnys enables complete automated characterization of a blood sample with only 4 to 6 wells.
This is a real leap in productivity compared to the 16 wells required to obtain the same results using card gel technology!
This performance opens up new perspectives for increasing your productivity and speeding up your operations while saving human resources.
Minimize waste
Omnys dramatically reduces the amount of infectious lab waste and plastic needed to perform blood tests, as well as transportation costs.
A tangible contribution to your sustainability goals!
Enlarge sample characterization without any additional costs
With complementary data and embedded controls at no additional cost, Omnys takes compatibility a step further. Move to the next-generation of blood typing and ensure maximum donor/patient compatibility!
100 % compatible with current reagents, buffers and protocols
The Omnys solution is compatible with all existing blood grouping protocols and seamlessly integrates in any blood transfusion workflow.
The Omnys solution
Fully automated high-throughput batch test system
The Omnys solution is based on the latest generation of automated sample processing, from centrifugation to test analysis.
- 2 pipeting arms
- 3 centrifuges
- 1 picture acquisition module.
High-resolution versatile 8-wells foils
Omnys foils incorporate exclusive technologies developed by Innobiochips to perform up to 20 high-definition biological tests per well and per sample.
Omnys ABO/D
Typing and Serotyping
Omnys PHENO
Phenotyping Rh/Kell
Omnys IAT
Antibody Screening
Omnys ExtPHENO
Extended Phenotyping
User-friendly software
Omnys software combines data, quality control, sample and instrument management in one comprehensive solution.
Ready-to-use Reagents
Omnys uses the usual controls, reagents and buffers to carry out the tests.
Opening early 2025
Join our beta testing program!
Innobiochips invites blood banks, healthcare institutions and transfusion specialists to take part in a unique beta testing program for the Omnys solution.
The Innobiochips team offers a six-month trial period designed to evaluate and incorporate the Omnys solution in your transfusion management workflow
- Installation of the Omnys solution
- Training: sample preparation, use, reading results.
- User assistance
Innobiochips has developed two major innovative diagnostic solutions in specific diagnostic areas: Transplantation, Transfusion, Infectious Diseases and Chronic Inflammatory Diseases. These solutions are based on a portfolio of proprietary technologies that enable the large-scale deployment of complex, multiplexed, high-resolution biological assays.
The next generation blood testing technology
Omnys provides high resolution testing of blood components: Standard ABO/D typing, phenotyping, advanced phenotyping and IAT. Omnys enables clinicians to perform multiplex testing with unmatched accuracy, reliability, efficiency... and minimal sample volume! These exclusive technologies are automated and fit into any blood transfusion workflow.
A new standard for In Vitro Diagnostics
Siryus is the most powerful multiplex immunoassay technology available today. It combines exclusive surface functionalization and printing for ultra-precise analyte detection. Accessible, scalable and easy to implement on standard instrumentation, Siryus has opened new possibilities for building automated, specific, comprehensive and highly sensitive diagnostic solutions. It has been incorporated into several diagnostic solutions for transplantation, covid testing and chronic inflammatory diseases analysis.
Over the last 10 years and the development of various applications in different fields of application, Innobiochips has built up a wealth of experience which is a veritable library of resources available for further needs. This in-depth knowledge of the issues and challenges faced by players in the diagnostics and healthcare sectors is an essential source of inspiration for innovations that are as close as possible to patients' needs.
Transplantation
Transplantation is a critical treatment that faces many challenges to ensure perfect donor/recipient compatibility. Innobiochips has adapted its Siryus technology to offer a novel solution to assess the recipient's reaction to their transplant in order to drastically reduce rejection.
Transfusion
Blood grouping approaches have not evolved in years. The process remains highly repetitive and resource intensive. Innobiochips will introduce a next-generation blood testing and grouping solution: Omnys. Based on breakthrough technologies, Omnys enables high-resolution testing of blood components: Standard ABO/D typing, phenotyping, extended phenotyping and IAT.
Infectious diseases
Innobiochips is at the forefront of developing high-resolution multiplex assays that are revolutionizing infectious disease diagnostics. In particular, our team has developed the most advanced COVID-19 diagnostic tool based on its proprietary technology: Covidiag.
Microbiota
Advances in molecular biology have revealed the intricate relationship between the microbiota and various diseases, providing unprecedented opportunities for novel diagnostic solutions. Innobiochips' high-resolution multiplexed diagnostic technologies can detect and characterize anti-microbiota antibodies, providing accurate and valuable insights into an individual's health status.
Innobiochips is a pioneering international diagnostics company. In close collaboration with scientists and healthcare professionals, we design, develop and manufacture next-generation tests for the development of more personalized, accurate and sustainable healthcare.
Joining Innobiochips means becoming part of a highly motivated team working together to improve diagnostic technologies for better health worldwide.